Asset Details
Do you wish to reserve the book?
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Do you wish to request the book?
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
2025
Overview
Donor-derived fecal microbiota treatments are efficacious in preventing recurrent
Clostridioides difficile
infection (rCDI), but they have inherently variable quality attributes, are difficult to scale and harbor the risk of pathogen transfer. In contrast, VE303 is a defined consortium of eight purified, clonal bacterial strains developed for prevention of rCDI. In the phase 2 CONSORTIUM study, high-dose VE303 was well tolerated and reduced the odds of rCDI by more than 80% compared to placebo. VE303 organisms robustly colonized the gut in the high-dose group and were among the top taxa associated with non-recurrence. Multi-omic modeling identified antibiotic history, baseline stool metabolites and serum cytokines as predictors of both on-study CDI recurrence and VE303 colonization. VE303 potentiated early recovery of the host microbiome and metabolites with increases in short-chain fatty acids, secondary bile acids and bile salt hydrolase genes after antibiotic treatment for CDI, which is considered important to prevent CDI recurrences. These results support the idea that VE303 promotes efficacy in rCDI through multiple mechanisms.
Results of multi-omic profiling of the microbiome and host immunity of individuals treated with VE303 to prevent recurrent
Clostridioides difficile
infection in the context of a phase 2 trial show robust colonization of VE303 and indicate potential biomarkers of response.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Adult
/ Anti-Bacterial Agents - therapeutic use
/ Bile Acids and Salts - metabolism
/ Biomedical and Life Sciences
/ Clostridioides difficile - pathogenicity
/ Clostridium Infections - drug therapy
/ Clostridium Infections - microbiology
/ Clostridium Infections - therapy
/ Fecal Microbiota Transplantation - methods
/ Feces
/ Female
/ Gastrointestinal Microbiome - genetics
/ Humans
/ Male
